在这项最新的研究中，人工智能模型接受了23万名患者超过120万对的心电图-超声心动图的对照训练，以检测多种形式的结构性心脏病。此后，团队对近 85000名此前未做过超声心动图检查且正在接受心电图检查的患者使用了EchoNext筛查工具，EchoNext识别出超过7500名存在未确诊的结构性心脏病的高风 险。在这些被EchoNext认定为高风险的人群中，有超过一半人接受了超声心动图检查。结果显示，AI工具对结构性心脏病诊断的准确率高达77.3%。 研究团队将EchoNext模型与人类心脏病专家进行了比较，共有13位心脏病专家对3200份心电图的评估（其中1600份使用AI辅助，1600份未使用AI辅助，每 位心脏病专家平均评估了246份心电图）来诊断结构性心脏病。结果显示，在未使用AI辅助的情况下，心脏病专家的准确率为64%；在使用AI辅助的情况 下，心脏病专家的准确率提升至69.2%，但仍低于EchoNext模型检测的77.3%的准确率。 由于缺乏常规且经济有效的筛查测试，许多有结构性心脏问题的人直到心脏功能严重受损时才被发现。 早期发现结构性心脏病对于改善预后至关重要，但广泛筛查仍然受限于超声心动图等影像工 ...

对于为何提前换届和经营业绩等问题，记者致电宝莱特并发去采访邮件，接线工作人员表示，暂无更多 回应。 距本届董事会任期届满尚有半年时间 宝莱特成立于1993年，总部位于广东省珠海市，控股股东和实际控制人为燕金元、王石夫妇，公司主营 业务为医疗器械产品研发、生产、销售、服务，主要涵盖生命信息与支持和肾病医疗两大业务板块。其 中，生命信息与支持板块主要产品为监护仪设备、心电图机、输注液泵、脉搏血氧仪、监护系统、可穿 戴医疗产品等，目前监护设备已覆盖数千家医疗机构。 7月16日晚间，血透龙头宝莱特（300246.SZ，股价9.11元，市值24.1亿元）发布董事会提前换届公告 称，第八届董事会任期即将于2025年12月届满，结合公司实际情况，公司拟开展董事会提前换届选举工 作。 肾病医疗板块，主要产品为血液透析设备（机）、血液透析器、透析液过滤器、血液透析粉/透析液、 透析管路、穿刺针、消毒液、透析用制水设备等，广泛应用于急慢性肾功能衰竭领域的治疗。 根据公告，宝莱特第八届董事会非独立董事陈坚、廖伟、唐文普将不再担任公司非独立董事职务，陈坚 拟提名为第九届董事会独立董事。此次提前换届后，宝莱特第九届董事会拟由9名董事组 ...

Core Insights - A new algorithm developed by a team from Shanghai's Tenth People's Hospital can accurately identify ST-segment elevation myocardial infarction (STEMI) patients through standard 12-lead electrocardiograms (ECGs), potentially reducing mortality rates and the risk of sudden cardiac death [1][3][4] - The success rate of treating acute myocardial infarction is highly time-dependent, with a significant difference in mortality rates between patients receiving rapid treatment and those experiencing delays [3] - The integration of artificial intelligence (AI) in analyzing ECG waveforms is expected to optimize emergency decision-making and improve patient outcomes [3][4] Technology Development - The research team has developed a wearable 12-lead ECG vest, which has received national Class II medical registration and is now in mass production [4] - The vest automatically transmits ECG signals to the cloud, where software can provide alerts for myocardial infarction and malignant arrhythmias [4] - The team has compiled over 10,000 preoperative ECG data samples and is expanding its dataset to enhance the AI's ability to identify and locate myocardial infarction [4] Future Implications - The AI-driven ECG system aims to provide efficient early warnings for high-risk groups and postoperative patients, potentially lowering the incidence of myocardial infarction and sudden cardiac death [4] - The system may also enhance the capabilities of emergency departments and chest pain centers in identifying acute myocardial infarction, thereby improving patient prognosis [4]

Core Insights - The article discusses the integration of AI technologies in medical education and healthcare at Shandong University Qilu Medical College, emphasizing the role of AI as an assistant to doctors rather than a replacement [4][5][6]. Group 1: Historical Context and Institutional Overview - Shandong University Qilu Medical College has a rich history of over 160 years, originating from the establishment of Dengzhou Wenhuiguan in 1864, and has trained over 60,000 medical students [2]. - The college comprises seven schools, including the School of Basic Medicine, School of Public Health, School of Stomatology, School of Pharmacy, First Clinical School, Second Clinical School, and School of Nursing and Rehabilitation [2][3]. Group 2: AI's Role in Medical Education - AI is viewed as a tool to enhance medical education, with initiatives like the "Biomedicine Data Science" program aimed at training future leaders in AI applications in healthcare [6]. - The integration of AI in teaching includes the use of standardized patients and digital anatomy systems, which improve the learning experience for medical students [7]. Group 3: AI's Impact on Healthcare Services - AI technologies have been implemented in various clinical applications, such as intelligent diagnostic systems for imaging and pathology, which assist doctors in making informed decisions [4][5]. - The use of AI has reportedly reduced the drug development cycle by 30%, exemplified by the accelerated evaluation of COVID-19 treatments [8]. Group 4: Future Directions and Innovations - The college is exploring advanced training methods, including the use of surgical robots and virtual reality simulations, to prepare students for future medical practices [9]. - AI is expected to play a significant role in optimizing healthcare delivery, with ongoing projects receiving substantial funding, such as a recent 120 million yuan grant for AI drug evaluation [8].

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices [1] - The company is recognized as one of the earliest domestic enterprises in China to develop and manufacture medical monitors, with its monitoring equipment covering thousands of medical institutions [1] Product Categories - The company offers a wide range of monitoring products, including integrated monitors, modular monitors, and handheld monitors, as well as infusion pumps, ECG machines, and central monitoring systems [1] - In the home healthcare sector, products include pulse oximeters and wearable medical devices like Doppler fetal heart monitors [2] - In the nephrology field, the company has a complete industrial chain with eight consumable bases and three channel platforms, providing hemodialysis equipment and related products [2] Recent Product Launches - In 2024, the company developed a polypropylene (PP) shell hemodialyzer and a special formula hemodialysis concentrate, both receiving Class III registration [3] - In April 2025, two new products were introduced: BioView anesthesia video laryngoscope and S200 smart enteral nutrition pump, with advanced features for improved patient care [3] Market Growth - As of the end of 2023, there were 916,600 hemodialysis patients in China, an increase of 72,300 from the end of 2022, maintaining an annual compound growth rate of over 10% for nearly a decade [5][6] Future Development Focus - The company aims to enhance its product development in the life information and support sector, focusing on clinical needs and integrating intelligent technology into new products [8] - In the nephrology sector, the company will continue to develop differentiated hemodialysis consumables and explore more technologies related to peritoneal dialysis and CRRT [8] Strategic Goals for 2025 - The company will concentrate on its two main businesses, targeting high-margin products in critical care and surgical anesthesia, while leveraging opportunities from medical infrastructure expansion and hospital upgrades [9][10] - Plans include enhancing production efficiency across national bases and embracing centralized procurement policies to improve overall operational efficiency [10]

其一，健康理念逐渐转变，全民健康意识显著增强。一方面，银发经济正不断催生新的养老需求。医疗 技术的进步和健康知识的普及，使中老年人的寿命得到延长，他们拥有更多时间和资源去享受生活，开 始崇尚积极的、全面的健康管理和生活方式，追求智慧养老、康养旅居等新型养老服务。数据显示，当 前我国康养旅居消费超2万亿元，占银发经济规模总量近20%，增速显著高于传统旅游业。另一方面， 年轻人也偏爱健康管理，并成长为健康消费主力军。与老一代人热衷于"囤东西"不同，以Z世代为代表 的年轻群体更愿意"囤健康"，普遍将健康消费视为"爱自己"的方式，以防患于未然为主要目的的消费成 为主流趋势。此外，部分年轻人生活节奏快、工作压力较大，受到亚健康、慢性病年轻化等问题困 扰，"主动管理"的健康意识与健康需求同步提升。 当前，我国居民健康素养水平大幅提升，健康产业市场规模不断扩大，健康消费发展潜力得到持续释 放。相关监测结果显示，2024年我国居民健康素养水平达31.87%，较2012年提高了23.07个百分点。 2024年我国大健康产业总收入规模有望达9万亿元。今年3月，《提振消费专项行动方案》出台，强调支 持新型消费加快发展，并作出相关部 ...

中国质量新闻网讯（许创业）近日，国家知识产权局发布了第二十五届中国专利奖授奖决定，来自深圳 坪山的比亚迪股份有限公司、深圳市联赢激光股份有限公司、富满微电子集团股份有限公司、深圳新宙 邦科技股份有限公司、深圳邦健生物医疗设备股份有限公司、深圳市曼恩斯特科技股份有限公司等分别 荣获不同奖项。其中在新能源汽车产业领域厚积薄发的比亚迪，本次在专利和外观设计上均荣获一项金 奖。 近年来，坪山企业展现出强大的创新能力和知识产权管理能力。以比亚迪为代表的头部企业，在高价值 专利创造上保持了强大的实力和技术创新优势；辖区生物医药、新能源、智能制造等战略新兴产业呈现 蓬勃发展的良好势头，推动辖区创新主体在技术创新领域结果。 坪山区通过深入实施创新驱动发展和知识产权强区战略，全面推进知识产权高质量创造、高效益运用、 高标准保护、高品质服务。PCT国际专利申请量持续增长，高校和科研机构专利转化有新突破，知识产 权服务业规上企业营收增速全市居前，深圳市市场监督管理局坪山监管局查处重大侵权盗版案件获国家 版权局奖励。 2024年，坪山区专利授权总量超1.1万件，其中发明专利授权量占比超1/4；有效发明专利同比增长 24.03%，有效 ...

Core Insights - The article highlights the transformation of grassroots healthcare in Sichuan, focusing on the integration of technology and expert resources to enhance rural medical services [1][9] Group 1: Challenges in Rural Healthcare - Traditional village doctor training faces issues such as lack of systematic training, practical guidance, and technology updates, hindering the goals of hierarchical diagnosis and health management [2] - Common problems identified in rural healthcare include insufficient knowledge and skills among village doctors, weak service attractiveness, and difficulty accessing quality resources [1][2] Group 2: Innovative Solutions - The "charging meetings" initiative in Meishan allows village doctors to gather monthly to discuss challenges and learn new skills, significantly increasing their patient volume and shifting focus from treatment to prevention [2][3] - The establishment of "resident mentors" in health centers provides ongoing practical training for village doctors, enhancing their capabilities and service quality [2][3] Group 3: Enhanced Service Offerings - The introduction of "director clinics" in health facilities allows senior management to provide direct patient care, fostering a sense of community and trust among patients [6] - The "tidal-style" medical service model in scenic areas addresses seasonal healthcare demands, ensuring timely medical attention for tourists and locals alike [6] Group 4: Resource Allocation and Quality Improvement - The implementation of "famous doctor workstations" and integration of local medicinal resources into healthcare practices aim to provide consistent quality medical services in rural areas [7][8] - The establishment of shared medical resources and remote consultation systems has led to significant increases in patient visits and improved access to specialized care [8] Group 5: Systematic Reforms and Future Directions - The article emphasizes the need for a systematic approach to rural healthcare reform, focusing on talent development, innovative service models, and resource allocation mechanisms [9][10] - The goal is to create a sustainable healthcare environment where every village has reliable medical professionals, accessible technology, and dependable services [11]

乐心医疗（300562）公告，控股子公司瑞康宏业近日收到广东省药品监督管理局下发的《受理凭证》， 获悉瑞康宏业变更医疗器械注册证事宜已获受理。本次变更产品为动态心电图系统，申请事项为第二类 医疗器械注册证变更，受理号为0010600420250551，分类为II类，规格型号为G12、G12plus。主要变更 内容为根据最新行业标准提高产品技术要求。上述事项有助于公司产品进一步符合行业最新标准，提升 产品竞争力。 ...

5月28日，宝莱特今日收盘7.31元，下跌1.35%，最新市净率1.64，总市值19.34亿元。 截至2025年一季报，共有3家机构持仓宝莱特，其中其他2家、基金1家，合计持股数623.43万股，持股 市值0.43亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)16宝莱特-31.90-27.071.6419.34亿行业平均 48.8147.104.62105.75亿行业中值35.4637.052.4048.69亿1天益医疗-1731.42-2965.731.8522.06亿2澳华内 镜-615.52308.724.9364.87亿3诺唯赞-394.38-466.452.1684.40亿4爱朋医疗-347.79264.224.1928.54亿5博晖 创新-323.49513.323.4547.46亿6硕世生物-134.75-1969.031.2139.41亿7奥精医疗-127.64-187.081.6823.69亿 8睿昂基因-99.17-81.421.4112.84亿9康泰医学-85.71-72.413.0656.41亿10中红医疗-71.83-57.300.9149.92亿 11华大智造-55 ...